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Despite its relatively low incidence, pancreatic cancer was the fourth leading cause of 
cancer-related death in the US in 2015. This is due in part to pancreatic cancer’s natural 
resistance to both chemotherapy and radiotherapy. Immunotherapy presents an attractive 
potential treatment approach, but initial trials in mice have proved ineffective.   Because cancer 
cells exhibit a significant increase in metabolic activity relative to normal tissue, an 
understanding of the metabolic function of tumors in systems with different levels of 
immunocompetence is a critical first step to develop an understanding of the immune-related 
metabolic properties of the tumor, which have potential application in assessing a tumor’s 
response to immunotherapy.  
Magnetic resonance (MR) is an intrinsically low sensitivity technique, but dynamic 
nuclear polarization allows one to increase the MR signal by five orders of magnitude. As 
described by the Warburg effect, even in the presence of an ample amount of oxygen, tumors 
preferentially metabolize their energy via the inefficient process of glycolysis in which pyruvate 
is ultimately converted into lactate. Thus, by hyperpolarizing 
13
C-labelled pyruvate, one can 
spectroscopically observe the conversion of pyruvate to lactate in real time and quantify a 
tumor’s glycolytic conversion flux in vivo. In addition, the application of high-resolution 1H 
nuclear magnetic resonance metabolomics allows one globally analyze the entire water-soluble 
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metabolome and quantify the relative concentrations of each metabolite in an extracted tumor 
tissue sample. By applying MR spectroscopic imaging with hyperpolarized pyruvate and NMR 
metabolomics, this study identifies clear metabolic biomarkers that can facilitate the assessment 
of metabolic changes between pancreatic tumors in mice cultivated in both immunocompromised 
and immunocompetent environments.  
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1. Introduction and Background 
1.1 Pancreatic Cancer 
In 2015, nearly 49,000 new cases of pancreatic cancer were diagnosed in the United 
States [1]. Despite this low incidence relative to other malignancies, pancreatic cancer was the 
fourth leading cause of cancer-related death in both men and women, as it was responsible for 
over 40,000 mortalities [1] in the United States in 2015 alone.  Pancreatic cancer has an abysmal 
five-year survival rate of 7 %
 
[1], and the median survival of patients diagnosed with a pancreatic 
malignancy is typically measured in months
 
[2].  One of the main factors leading to pancreatic 
cancer’s exorbitantly high rate of morbidity is its natural resistance to both chemotherapy and 
radiotherapy
 
[3]. Thus, it is pertinent to explore new treatment modalities that can potentially 
extend the lives of these patients without compromising their quality of life.  
The pancreas is a small, pear-shaped organ found in the upper left quadrant of the 
abdominal cavity
 
[4]. It is located behind the stomach, sits on top of the curve of the duodenum
 
[5], and rests below the liver. The pancreas has functional roles in both the endocrine and 
digestive systems [6].  The main endocrine function of the pancreas, spearheaded by the islets of 
Langerhans
 [7], is to produce insulin and glucagon, hormones that regulate the body’s blood 
glucose level [8-11]. The main digestive function of the pancreas is the production of the 
enzymes amylase, lipase, and trypsin which are involved in the catabolism of starch, fat, and 
polypeptides, respectively
 
[12]. Numerous epidemiological studies [13-15] have identified age
 
[16] and cigarette smoking [17,18] to be the two most commonly reported risk factors for 
pancreatic cancer. Other potential risk factors include alcohol consumption [19,20], family 
history [21,22], and occupational exposure to carcinogens [23,24].  
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Pancreatic ductal adenocarcinoma is far and away the most common form of pancreatic 
cancer [25]. Like many other malignancies, pancreatic ductal adenocarcinoma is known to be 
caused by the accumulation of acquired genetic mutations [26]. Greater than 85% of pancreatic 
carcinomas exhibit K-ras mutations [27-29], which are strongly correlated with both alcohol and 
cigarette consumption [30-32]. In addition, the tumor-suppressor genes TP53 [33], SMAD4 [34], 
CDKN2A [35], p16 [36-38], and MADH4 [39] are often inactivated in pancreatic tumors. As in 
other types of cancer, many growth factors and their receptors are overexpressed in pancreatic 
malignancies. Vascular endothelial growth factor [40,41] and interleukin 8 [42] are both 
overexpressed in pancreatic cancer and are critical in initiating angiogenesis which is necessary 
to satisfy the tumor’s increased demand for nutrients and oxygen [43].  Other studies have shown 
that fibroblast growth factor [44], epidermal growth factor [45], tumor necrosis factor α [46], 
transforming growth factor β [47], interleukin 1 [48], and interleukin 6 [49] are also upregulated 
in pancreatic tumors.  
When determining treatment approaches it is often helpful to classify pancreatic tumors 
into three categories: localized and resectable, locally advanced and unresectable, or metastatic 
[50]. A pancreatic tumor is deemed localized and potentially resectable if it does not encroach on 
the superior mesenteric artery or the coeliac axis and there is no evidence of distant metastatic 
disease [26].   Pancreatic tumors are classified as resectable in approximately 15-20% of patients 
and are often treated with a pancreaticoduodenectomy and adjuvant fluorouracil-based 
chemoradiation [51]. The five-year survival of these patients improves to 20% [52].  A locally 
advanced and unresectable tumor is defined as such when the disease encases a vascular 
structure but there is still no evidence of distant metastatic disease [26]. The standard of care for 
these patients is fluorouracil-based chemoradiation [53]. Treatment approaches for metastatic 
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pancreatic cancer are only palliative [54] in nature. The chemotherapeutic agent gemcitabine 
serves as the standard of care when there is evidence of distant metastatic disease
 
[55]. 
 
1.2 The Immune System 
 The immune system is a functional biological system consisting of cells, tissues, and 
organs that protect a host from foreign invaders [56].  It is conventionally dichotomized into two 
intrinsic defense systems [57] that act independently of each other: the innate defense system and 
the adaptive defense system. The innate immune system is nonspecific [58] and contains two 
lines of defense. The first line of defense includes external body membranes, namely the skin 
and mucous membranes [59] that act as a physical barrier against pathogens and other foreign 
invaders.  
The second line of defense utilizes phagocytes [60], natural killer cells [61], and 
antimicrobial proteins [62] to fight off pathogens when the first line of defense has been 
compromised. Phagocytes, such as macrophages [63] and neutrophils [64], ingest foreign 
bacteria in a process known as phagocytosis [65,66]. Natural killer cells, a group of defensive 
cells found mainly in lymph
 
[67], kill target invaders by inducing them to undergo apoptosis 
[68]. Antimicrobial proteins, such as interferons [69] and complement proteins [70], contribute 
to the innate defense system by either attacking microorganisms directly or by obstructing their 
propensity to reproduce. Inflammation, a response intended to prevent the spread of harmful 
agents to neighboring tissue, to remove cellular debris and other pathogens, and to set the stage 
for the repair process to begin, is a hallmark of the second line of defense [71].  
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 The adaptive immune system is characterized by three notable properties. Firstly, it is 
specific, as the adaptive immune response is initiated by specific pathogens and foreign 
substances. It is systemic, as the adaptive immune response is not limited to the site of the initial 
infection. Lastly, it has the ability to remember pathogens after an initial exposure and will 
subsequently mount an even stronger attack against these previously encountered foreign 
substances [71]. The adaptive immune system can be further subclassified into humoral 
immunity [72] and cell-mediated immunity [73].   
Humoral immunity is mediated by antibodies [74] located in the fluids of the body, 
namely blood and lymph [75]. These antibodies, also called immunoglobulins [76], are secreted 
by B lymphocytes [77] in response to a particular invading antigen [78]. The antibody then binds 
with the antigen at a specific binding site [79,80] to form an antibody-antigen complex [81,82], 
which causes the antigen to be rendered inactive via neutralization [83] and tagged for 
destruction via agglutination [84], precipitation [85], or complement fixation [86]. 
Cell-mediated immunity is controlled directly by T lymphocytes [87]. These T 
lymphocytes are activated in a two-step process [88] both involving interactions with antigen 
presenting cells. First T cell antigen receptors bind to an antigen-major histocompatibility 
complex at the surface of an antigen presenting cell [89]. Then the T cell receptors induce a 
costimulatory signal when they bind with molecules on antigen presenting cells [90]. Signaling 
in cell-mediated immunity is controlled by a class of proteins known as cytokines [91], which 
include both interferons [92] and interleukins [93]. There are many types of T lymphocytes that 
contribute to cell-mediated immunity; important examples include helper T cells [94], cytotoxic 
T cells [95], and regulatory T cells [96]. Helper T cells aid in the activation of B and T 
lymphocytes and induce B and T cell proliferation [97]. Cytotoxic T cells, as the name implies, 
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can directly attack and kill antigens [98].  Regulatory T cells lessen the immune response [99] by 
releasing inhibitory cytokines [100].  
1.3 Immunotherapy 
 As mentioned previously, one of the causes leading to the exorbitantly high morbidity of 
pancreatic cancer is its intrinsic resistance to both chemotherapy [101,102] and radiotherapy 
[103]. Immunotherapy has exhibited substantial success in treating other forms of cancer such as 
melanoma [104], so there was much hope [105] that it would be implemented into pancreatic 
cancer with equal success and provide an attractive new treatment options to numerous 
pancreatic cancer patients.  
The aim of immunotherapy in cancer is to stimulate an effective immune response in the 
patient against his or her tumor [106]. This can be accomplished by stimulating the recruitment 
and activation [107,108] of T cells that can recognize tumor-specific antigens. In addition, 
monoclonal antibodies can also activate and inhibit molecules of the immune system and, as a 
result, induce an antitumor immune response [109]. Moreover, monoclonal antibodies can be 
conjugated to either chemotherapeutic [110] or radiotherapeutic [111] agents and have been 
implemented in treating lymphoma [112-118], leukemia [119,120], and other hematologic 
malignancies [121]. Both approaches, the recruitment and activation of T cells and monoclonal 
antibodies, present attractive options towards the treatment of pancreatic cancer [122].  
Although not originally recognized as such [123], immune evasion is now considered one 
of the hallmarks of cancer [124]. Tumor cells learn to survive in a chronically inflamed 
microenvironment, evade immune recognition, and suppress immune responses [125,126]. In 
particular, the inhibition of T cell recognition of pancreatic tumors and the subsequent 
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suppression of the immune response may be due to many factors [122] such as the upregulation 
of molecules involved in immune inhibition [127-134], deficiencies in immune-cell localization 
[135-148], the loss of immune-regulation signals [149-151], and the loss of co-stimulatory 
factors [152-154]. The progression of a successful immune response mandates that many 
immunological checkpoints be passed [155]. Thus, any clinically successful immunotherapy 
must be able to overcome these inhibitory checkpoints [156]. 
One key type of the immunotherapeutic approach takes advantage of the receptor [157-
159] program death 1 (PD-1) and its ligands PD-L1 and PD-L2 [160]. PD-1 is a receptor of the 
immunoglobulin superfamily that downregulates T cell antigen receptor signaling [161]. In 
particular, when PD-L1 or PD-L2 bind to PD-1, an inhibitory signal [162-164] is transmitted to 
the T cell, which reduces cytokine production and suppresses T cell proliferation [165]. PD-L1 is 
commonly overexpressed in tumors [166-169], and the expression of PD-L1 is negatively 
correlated with survival in pancreatic cancer [170].  Thus, treatment with PD-L1 neutralizing 
antibodies will downregulate PD-L1 expression and, as a result, inhibit the suppression of T cell 
proliferation [171,172]. Other treatment approaches that block the inhibitory effects of the 
receptor Cytotoxic T lymphocyte- associated antigen 4 (CTLA-4) are currently being explored 
by MD Anderson immunologist James P. Allison and others [173-188].  
Despite the incredible potential, initial trials implementing immunotherapy into 
pancreatic cancer treatment regiments have been disappointing [189-192], and the reasons as to 
why are not well understood.  An overarching goal in the community is to obtain a more 
mechanistic understanding of immunotherapy’s failure in pancreatic cancer, but this is a very 
complex problem that must be approached from numerous angles. Because metabolic function is 
severely dysregulated in cancer [193], one avenue of approaching this problem is through 
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studying the immune-related metabolic properties of pancreatic cancer. More specifically, 
observing the metabolome of pancreatic tumors cultivated in different immune environments 
could serve as a critical first step in understanding the failure of immunotherapy in pancreatic 
cancer.  
 
1. 4 Cancer Metabolism 
 Metabolism is the net sum of all the physical and chemical processes taking place within 
an organism that result in the biological processing of energy and materials [194]. Metabolism is 
typically subdivided into two categories [195]: catabolism and anabolism. Catabolism is the 
breakdown of complex molecules into simpler end products and results in the release of chemical 
energy [196]. Anabolism, on the other hand, is the buildup of simple molecules into larger, more 
complex units and necessarily requires the input of energy [197]. Most metabolic reactions are 
catalyzed by enzymes, so the vital regulation of metabolic function is accomplished via the 
modulation of the activities of these enzymes [198]. 
Metabolic function is severely dysregulated in cancer [199], and this dysregulation of 
metabolism is considered one of the hallmarks of cancer [200,201]. Normal differentiated cells 
typically metabolize energy via oxidative phosphorylation under standard oxygen conditions but 
switch to anaerobic glycolysis under hypoxic conditions [202].  In contrast, even in the presence 
of an ample supply of oxygen, tumor cells tend to metabolize energy via the inefficient [203] 
process of glycolysis rather than the more energy-efficient process of oxidative phosphorylation 
[204-209]. This upregulation of aerobic glycolysis [210,211] in cancerous cells ultimately leads 
to an increased production of lactic acid [212] relative to healthy cells. This phenomenon was 
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first described [213] by Otto Warburg [214-216] in 1924 and has since been coined the Warburg 
effect [217-220].  Because metabolomics is downstream from gene expression and protein 
synthesis [221,222], studying the metabolism of pancreatic tumors cultivated in different 
immune environments may provide crucial insight into how the immune environment alters the 
function of pancreatic tumor cells.  
 
1.5 NMR Spectroscopy 
The first magnetic resonance-based technique used in this project to interrogate tumor 
metabolism was nuclear magnetic resonance (NMR) metabolomics. NMR metabolomics is a 
spectroscopic technique that allows one to quantitatively interrogate the water-soluble 
metabolome. It relies upon the same guiding principles as magnetic resonance imaging (MRI) 
except for the fact that the gradient coils responsible for spatial encoding in MRI are not present 
in NMR.  
 
Figure 1-1: A representative NMR spectrum 
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As in MRI, a strong, static magnetic field is established to polarize the spins, resulting in 
a net magnetization in the direction of the field. This magnetization is then transferred into a 
plane orthogonal to the direction of the field via a pulse of electromagnetic radiation in the 
radiofrequency regime. These spins will precess about the magnetic field, and, by Faraday’s law 
of induction [223-225], this changing magnetic field will induce an electromotive force, which 
can be detected and measured as a current through a coil. The chemical environment in which a 
proton is located will perturb the magnitude of the net magnetic field experienced by that proton 
[226]. Thus, a proton in a given molecule will experience a slightly different magnetic field than 
a proton in a different molecule or even a nonequivalent proton in that same molecule. Since the 
precessional frequency of a spin, known as the Larmor frequency [227], is proportional to the 
magnetic field experienced by that spin, protons in different chemical environments will precess 
at slightly different frequencies. Therefore, the signal detected in the coil will be a superposition 
of numerous, individual frequency components. By taking the Fourier transformation of this 
signal, one can transform the signal into the temporal frequency domain to obtain an NMR 
spectrum, as shown in Figure 1-1. Here, the vertical axis represents relative signal intensity, 
while the horizontal axis represents chemical shift which is a relative measure of deviation from 
a standard resonance frequency. Chemical shift is measured in parts per million (ppm) relative to 
the Larmor frequency of a spin subject to the static magnetic field. A group of equivalent protons 
in a given molecule will resonate at a specific chemical shift, so it is possible to identify the 
presence of certain metabolites by observing the location of the peaks in the NMR spectrum. The 
relative concentration of these metabolites can then be determined by integrating under a given 
peak in the frequency domain [228-232].  
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It is important to note that NMR metabolomics provides a static snapshot of pancreatic 
tumor metabolism literally frozen in time. The samples that we subject to NMR spectroscopy 
have been resected from mice following euthanasia and flash frozen. Thus, we are observing the 
static metabolic properties of that tumor at the time of euthanasia. In addition, NMR 
metabolomics, in theory, allows us to globally analyze the entire water-soluble metabolome. 
Because there can be multiple unrelated molecules that resonate at the same chemical shift, it is 
not always possible to identify every molecule with 100% certainty. However, many of the 
common metabolites and metabolic pathways are easily identifiable, so a large amount of 
metabolic information can be ascertained in an NMR spectroscopic experiment.  
 
1.6 Hyperpolarization 
Although the static, ex vivo data obtained in NMR metabolomics are very illuminating, it 
is also advantageous to interrogate real-time tumor metabolism in a living system. Unfortunately, 
however, MRI is a relatively low sensitivity technique [233]. This is due to the fact that when a 
sample is placed in a magnetic field, the spins in the sample will either align or anti-align with 
the field [234,235].  Aligning with the field is a lower energy state than anti-aligning, so the 
number of spins that will align with the field, N-, will be greater than the number of spins that 
anti-align, N+. In particular, the net NMR signal is proportional to the polarization, P, which is 
given by the following relation [236]: 
   
|     |
     
     (
    
    
)       Equation (1) 
Here, γ is the gyromagnetic ratio of the nucleus, ħ is the reduced Planck’s constant, B0 is the 
strength of the static magnet field, kB is the Boltzmann constant, and T is the temperature. At 
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typical clinical field strengths, for every million spins, only a few more spins populate the lower 
energy state. Since the net magnetization is the vector sum of the individual dipole moments, it is 
proportional to the difference of the number of spins that align with the field and the number of 
spins that anti-align with the field [237]. This sensitivity problem is typically avoided since most 
clinical imaging techniques focus on hydrogen atoms [238]. Sensitivity issues are not as dire in 
hydrogen-based MRI due to the high natural abundance of hydrogen in the body [239-240] and 
its comparably large gyromagnetic ratio of 42.58 MHz/T [241]. If one wishes to image MR-
visible nuclei other than hydrogen, however, one needs a technique that increases sensitivity.    
 
Figure 1-2: The HyperSense DNP Polarizer used at MD Anderson  
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Figure 1-3: A T2-weighted coronal image that illustrates two dimensions of the voxel in 
which spectroscopic data are acquired  
Hyperpolarization refers to the driving of the nuclear spin polarization far from its 
thermal equilibrium distribution [242]. In particular, spins are preferentially driven to a given 
energy state so that the signal is enhanced considerably [243]. Hyperpolarization can be achieved 
through a variety of methods: optical pumping [244], parahydrogen-induced polarization [245-
247], brute force polarization [248-249], and dynamic nuclear polarization (DNP). The preferred 
hyperpolarization technique of focus in this treatise was DNP. Polarization of nuclear spins in 
DNP is accomplished in an amorphous solid state [250] at very low temperatures, on the order of 
1 K. Unpaired free electrons, in the form of an organic free radical, are added to the sample, and 
the high electron spin polarization is transferred to the nuclear spins via microwave irradiation 
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[251]. At MD Anderson, this is accomplished using a HyperSense DNP Polarizer, shown in 
Figure 1-2, that is produced by Oxford Instruments. This mechanism of polarization transfer was 
originally proposed by the physicist Albert Overhauser [252] in 1953. Previous studies have 
demonstrated that polarizations of nearly 100% and 50% can be achieved for 
1
H and 
13
C, 
respectively [253,254], which constitutes a greater than 10,000-fold increase in sensitivity [255].  
 Because glycolysis, in which pyruvate is converted into lactate, is upregulated in cancer, 
pyruvate is the substrate that we choose to hyperpolarize to probe pancreatic tumor metabolism 
[256]. By observing the flux of pyruvate to lactate, one can obtain a measure of how glycolytic a 
tumor is [257]. This is accomplished by labelling pyruvate with 
13
C, hyperpolarizing the 
13
C, and 
injecting the labelled pyruvate into the subject. The pyruvate will perfuse into the tumor and be 
converted into lactate. This real-time pyruvate-to-lactate conversion is captured using dynamic 
magnetic resonance spectroscopic imaging (MRSI). Similarly to conventional magnetic 
resonance spectroscopic imaging, a voxel is placed over a region of interest in which 
spectroscopy is to be performed. Figure 1-3 illustrates the placement of this voxel on a coronal 
view of a T2-weighted anatomical scan of a mouse with a pancreatic tumor implanted in its flank. 
The voxel position is chosen as to contain as much of the tumor volume as possible. 
Spectroscopic data are acquired every two seconds, and these 
13
C spectra are integrated over 
time to produce a time-integrated 
13
C spectrum. Figure 1-4 depicts a representative time-
integrated spectrum acquired in one of our imaging experiments. Here, the vertical axis 
represents the relative signal intensity in arbitrary units, which is essentially the time integrated 
sum of all spectra acquired. The horizontal axis represents 
13
C chemical shift. Pyruvate and 
lactate are labelled in the figure for convenience. 
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Figure 1-4: A representative time-integrated spectrum  
 
Figure 1-5: A dynamic spectrum depicting the conversion of pyruvate into lactate 
15 
 
The individual peak intensities of pyruvate and lactate can be plotted as a function of 
time, as is shown in Figure 1-5. Here, pyruvate is shown in red, lactate is shown in blue, and the 
dots indicating the start time and end time of the pyruvate injection are shown in pink. 
Immediately following injection, the pyruvate concentration rises rapidly and then decays via T1 
relaxation [258]. Shortly after the injection, one can see the lactate concentration rising, 
indicating its conversion from pyruvate. Ultimately, that signal also decays due to T1 relaxation.  
The glycolytic flux can be quantified using the metric nLac given the time-dependent 
concentrations of pyruvate [Pyruvate] and lactate [Lactate]: 
     
∫(         )  
∫(                     )  
      Equation (2) 
Essentially, nLac is the time-integrated hyperpolarized lactate concentration normalized by the 
total time-integrated hyperpolarized signal, pyruvate plus lactate. Here, the integrals run from t = 
0 to t = ∞.  
Magnetic resonance spectroscopic imaging of hyperpolarized pyruvate has its challenges. 
The biggest challenge faced is the spin-lattice relaxation of the hyperpolarized pyruvate [259], 
which depends on numerous factors but typically has a time constant on the order of tens of 
seconds to minutes [260].  Thus, the success of this technique inherently depends on the ability 
of the pyruvate to perfuse to the tumors rapidly relative to the T1 decay of the signal. This shall 
be discussed further in later sections.  
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1.7 Hypothesis and Aims 
The ultimate aim of this project was to interrogate the immune environment’s effect on 
the metabolism of pancreatic tumors. Pancreatic tumor metabolism has been probed using two 
different magnetic resonance-based techniques: nuclear magnetic resonance spectroscopy and 
magnetic resonance spectroscopic imaging of hyperpolarized pyruvate. These two techniques 
provide distinctly different yet complimentary information. NMR spectroscopy provides a static 
snapshot of tumor metabolism and allows one to interrogate the entire water-soluble 
metabolome. Most key metabolites can be identified, and their concentrations can be quantified. 
In addition, the metabolic pathways that are important in pancreatic tumor metabolism can be 
determined. MRSI using hyperpolarized pyruvate, on the other hand, focuses on a single 
metabolic pathway, aerobic glycolysis, by quantifying the glycolytic conversion flux from 
pyruvate to lactate. This technique provides a dynamic picture of pancreatic tumor metabolism 
and allows us to understand how pyruvate is metabolized in vivo. The specific aims of this 
project can be articulated as follows: 
Specific Aim 1: Perform NMR metabolomics to identify clear metabolic biomarkers 
characteristic of pancreatic tumors resected from mice with different levels of immune system 
functionality.  Studying the global metabolic profile of ex vivo tumors in systems with different 
levels of immunocompetence is a critical first step toward developing an understanding of the 
immune-related metabolic properties of the tumor, which have potential application in assessing 
a tumor’s response to immunotherapy. We hypothesize that it is possible to identify clear 
metabolic biomarkers that can predict the immune environment in which a pancreatic 
tumor was harvested. 
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Specific Aim 2: Quantify the pyruvate-to-lactate conversion flux of pancreatic tumors in living 
mice with different levels of immune system functionality via real-time hyperpolarized 
13
C 
pyruvate MRSI. Pyruvate-to-lactate flux is a well-established biomarker that can quantitatively 
assess how glycolytic a tumor is, which tends to correlate with tumor growth and aggressiveness.  
Normally, MR imaging is not sufficiently sensitive to image nuclei other than hydrogen.  
However, dynamic nuclear polarization (DNP) is a technique that allows us to preferentially 
drive nuclear spins to a given energy state and, as a result, increase the sensitivity of MR 
imaging by roughly five orders of magnitude.  This will allow us to image 
13
C-labeled pyruvate 
and capture its conversion to lactate in real-time. We hypothesize that pancreatic tumors 
harvested in different immune environments will exhibit different levels of dependence on 
aerobic glycolysis.     
 
1.8 Research Approach 
 Mice can be bred to possess varying levels of immunocompetence, which is an 
organism’s ability to produce a normal immune response after being exposed to an antigen [261]. 
In particular, the hairless mouse mutant breed typically referred to as “nude” mice is 
immunocompromised, as these athymic mice are born without the ability to produce viable T 
cells [262]. C57BL/6 mice, on the other hand, have a properly functioning immune system [263]. 
Pancreatic tumors were cultivated in both sets of mice, and the metabolism of both were 
observed in order to study the immune environment’s influence on pancreatic tumor metabolism. 
Both NMR spectroscopy and MRSI with hyperpolarized pyruvate were employed to study 
metabolism. In addition, these experiments were performed at two separate time points in tumor 
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development: one at an earlier stage when the tumors were small, ~1 cm in diameter, and one at 
a later time point when the tumors were larger, ~1.5 cm in diameter. 
 
2. Materials and Methods 
2.1 Mouse Model 
The animal model was developed in a collaborating laboratory and utilized both the 
immunocompetent C57BL/6 mice and the immunocompromised nude mice. All procedures were 
performed in accordance with regulations of the Animal Care and Use Committee of the 
University of Texas MD Anderson Cancer Center. 
 
Figure 2-1: A cohort of immunocompetent C57BL/6 mice  
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Figure 2-2: A cohort of immunocompromised nude mice  
 
Figure 2-3: A nude mouse with a subcutaneously-injected pancreatic tumor growing in its 
flank  
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A cohort of five C57BL/6 mice is shown in Figure 2-1, and a cohort of five athymic nude 
mice is shown in Figure 2-2. When the mice reached approximately nine weeks of age, our 
collaborators injected approximately one million K8484 pancreatic tumor cells into the flanks of 
the mice. This cell line was syngeneic to C57BL/6 background and derived from mouse tumors 
with an oncogenic KRAS mutation (G12D) and a homozygous null mutation in p53. A nude 
mouse with a subcutaneously injected tumor growing in its flank is shown in Figure 2-3. 
 
2.2 NMR Metabolomics Experimental Methods 
When the tumors reached their appropriate size, either approximately 1 cm or 2 cm in 
diameter, the mice were euthanized. The tumors were resected from the flank and immediately 
frozen in liquid nitrogen. The samples were then stored at -80ºC until further analysis was 
performed.   
Each sample was weighed, crushed, and immersed in 3 mL of methanol-to-water mixture 
(2:1) with 0.5 mL of polymer vortex beads inside a 15 mL test tube. Mechanical homogenization 
was performed by vortexing the tubes for 15 seconds, soaking the samples in liquid nitrogen for 
one minute, allowing the mixture to thaw, and repeating this process three times.. The samples 
were then subjected to centrifugation for ten minutes to physically separate the water-soluble 
metabolites from the proteins and other cellular constituents. The supernatant was extracted and 
subjected to rotary evaporation in order to remove the methanol. The samples were further 
dehydrated by placing them on a lyophilizer overnight, leaving just a collection of metabolites in 
powder form remaining. These metabolites were then immersed in a solution of 600 μL of 2H20, 
36 μL of PO4 buffer, and 4 μL of 80 mM DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid). The 
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PO
4
 buffer was added in order to stabilize any potential pH variations, and the DSS served as the 
reference standard to which we normalized the spectral signal from each metabolite.  
 NMR spectroscopy was performed on a Bruker AVANCE III HD
®
 NMR scanner (Bruker 
Bio Spin Corporation, The Woodlands, TX) at a temperature of 298 K.  The 
1
H resonant 
frequency was 500 MHz, which corresponds to a static field strength of 11.7 T. The scanner 
possesses a triple resonance (
1
H, 
13
C, 
15
N) cryogenic temperature probe with a Z-axis shielded 
gradient. Water suppression was performed using a pre-saturation technique. The spectra were 
collected with a 10240 Hz spectral width, a 90º pulse width, a scan delay of 6.0 s, and an 
acquisition time of 1.09 s (16,000 complex points). Two hundred and fifty-six scans were 
acquired and averaged, so that the total scan time was 32 minutes and 49 seconds. Here, trel + tmax 
was nearly 8 s so that it was greater than 3*T1 of the metabolites observed [264]. Apodization of 
the time domain signal was performed using an exponential function. The 500 MHz Bruker 
scanner used in all NMR metabolomics experiments is shown in Figure 2-4. Figure 2-5 depicts 
representative NMR spectra of tumor samples taken from the immunocompetent and 
immunocompromised mice. 
 After the spectra were acquired, metabolic profiling was performed in the Chenomx 
NMR Suite 8.1 software (Chenomx Inc., Edmonton, Canada). Quantification of the metabolites 
was then performed using the MestReNova software (Mestrelab Research, A Coruña, Spain) by 
integrating a nonzero region centered about the chemical shift at which the metabolite is known 
to resonate. This integral value is then normalized by the value of the integral of the DSS 
reference peak. Since the NMR signal is directly proportional to the amount of material in the 
test tube, this value is further normalized by the mass obtained prior to immersion in the 
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methanol-to-water mixture. Prior to integration, phase and baseline corrections were performed 
manually in MestReNova. 
  
Figure 2-4: A 500 MHz Bruker NMR spectrometer  
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Figure 2-5: Representative NMR spectra of tumor samples taken from the 
immunocompetent and immunocompromised mice 
 
2.3 Hyperpolarization Experimental Methods 
 20µL of [1-
13
C]-enriched pyruvic acid ( Isotec, Sigma-Alridch) samples containing 15 
mM OX63 trityl radical (Oxford Instruments Molecular Biotools, Abingdon, UK) were doped 
with 1.0  mM concentrations of  ProHance containing Gd
3+
 ions. Hyperpolarization was 
accomplished at 3.35 T and at the extremely low temperature of 1.4 K using a HyperSense DNP 
Polarizer (Oxford Instruments, Abingdon, United Kingdom). The pyruvic acid was bombarded 
with 94.082 GHz microwaves for approximately one hour so that the high electron spin 
polarization of the trityl radicals could be transferred to the nuclear spins at the 
13
C atoms in the 
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pyruvic acid. Since DNP must be performed in the solid state, the pyruvic acid was rapidly 
dissolved in Tris/EDTA and NaOH at 310.15 K, which yielded 80 mmol/L of pyruvate at a 
physiological pH. 200 μL of this hyperpolarized substrate was then injected into the mouse via a 
catheter inserted into the tail vein. The injection typically lasted from 10 to 12 seconds and was 
performed with the mouse placed in the lateral decubitus position. The mouse was anesthetized 
with isoflurane throughout the entirety of the procedure [265].  
 Each 
13
C spectrum was acquired using a 7 T Bruker scanner with a 30 cm bore BioSpec 
magnet. This small animal scanner is shown in Figure 2-6. The scanner was equipped with a 
Bruker gradient and shim system BGA-12 that has maximum gradient amplitude of 200 mT/m 
and a rise time of 80 μs. The linear radiofrequency coil was dual-tuned for both 1H and 13C and 
had a 36 mm inner radius.  T1-weighted proton images were taken for positioning, which were 
immediately followed by rapid gradient echo multiplane scout scans for localization. T2-
weighted scans were acquired in axial, coronal, and sagittal planes and subsequently used for 
positioning the voxel in which 
13
C spectroscopy is performed. The imaging parameters of the 
T2-weighted scans were: echo time TE = 17 ms, repetition time TR = 2.5 s, 4 cm field of view, 
156  μm x 156  μm in-plane resolution, 20º flip angle, ten 2-mm slices, and 4 averages [266].  
 A series of slice-selective 
13
C spectra (field-of-view 40 x 40 mm, slice thickness 8 mm on 
the tumor) were collected right after injection of hyperpolarized pyruvate using the spFLASH 
sequence. A total of 90 transients were acquired with the time delay between each transient being 
2 s (total time 3 minutes). Each transient utilized a 20
o
 flip angle of excitation pulse (Gauss 
pulse) and 2048 data points. Acquired data was processed both in MATLAB (MathWorks Inc., 
Natick, MA) and TopSpin (Bruker BioSpin GmbH, Ettingen, Germany). The dynamic spectra 
were manually phased and line-broadening was applied (10 Hz). The area under the spectral 
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peaks for pyruvate and lactate were integrated over the entire array. The normalized lactate 
(nLac) ratio was calculated as lactate over the sum of pyruvate and lactate signals. 
 
Figure 2-6: A 7 T Bruker small animal MRI scanner 
 
2.4 Statistical Methods 
To determine if statistical significance was achieved in both NMR spectroscopy and 
hyperpolarization experiments, we performed an unpaired, two-sample, two-tailed t-test with 
equal variance [267]. Significance was achieved if the p-value α < 0.05.  All statistical analyses 
were performed in Microsoft Excel (Microsoft Corporation, Redmond, WA).  
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3. Results 
3.1 NMR Spectroscopic Data 
 NMR spectroscopy was performed for tumors at a later time point in tumor progression, 
approximately three weeks after the tumor cells had been injected into the flank of the mice. The 
tumors at the time of euthanasia were approximately 2 cm in diameter. Spectroscopic data were 
collected for ten mice in total, five of which were nude mice and five of which were C57BL/6 
mice. Here, the immunocompetent C57BL/6 mice exhibited significantly higher baseline 
metabolic activity than the immunocompromised nude mice. This is illustrated in Figure 3-1 
where the relative concentration levels of various metabolites are shown for both cohorts of 
mice. The vertical axis depicts relative concentration, which is a unitless quantity that 
characterizes the concentration of the given metabolite per unit mg of sample relative to the 
concentration of the added reference standard. The horizontal axis depicts some of the common 
metabolites that were present in the spectra. The error bars shown in this figure are the calculated 
standard errors for a given metabolite found in a given group of mice. In particular, we observed 
significantly higher relative concentrations of the following metabolites: lactate (p = 0.020), 
alanine (p = 0.014), creatine (p = 0.00013), total choline (p = 0.046), methionine (p = 0.0015), 
glutamate (p = 0.018), glutathione (p = 0.012), oxaloacetate (p = 0.029), glycine (p = 0.015), 
aspartate (p = 0.0033), and taurine (p = 0.012).  
This metabolic difference between the immunocompetent mice and the 
immunocompromised mice was quite drastic, as it was observed that the immunocompetent mice 
are more metabolically active than the immunocompromised mice by an average of 93%. In 
Figure 3-2, a bar graph is presented that shows the ratio of metabolic concentration for a given 
27 
 
metabolite between the two cohorts of mice.  In this figure, each metabolite that was properly 
identified is shown, and one can see that the immunocompetent mice demonstrate higher 
baseline metabolic activity than the immunocompromised mice by a factor slightly less than two. 
Here, GPC is an abbreviation for sn-Glycero-3-phosphocholine, which along with 
phosphocholine is an important choline derivative [268].
  
Figure 3-1: Relative concentrations of various metabolites found in larger tumor samples 
Since there exist genomic differences between the two cohorts of mice, it was entirely 
possible that these metabolic differences are simply the product of these genomic differences and 
are not the metabolic properties of pancreatic tumors cultivated in different immune 
environments. Thus, a negative control experiment was performed in which the same two groups 
of mice, C57BL/6 and nude, were not injected with pancreatic tumors.  The mice were 
euthanized, and healthy pancreatic tissue was resected. NMR metabolomics was then performed, 
and the metabolic differences seen in the pancreatic tumor tissue samples were not observed. In 
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fact, many metabolites were found in slightly higher concentrations in the immunocompromised 
mice. The only exception to this was creatine in which the immunocompetent mice exhibited 
significantly higher concentrations (p = 0.036). Note, however, that this difference in creatine 
concentration in this negative control experiment is much less than that found in the pancreatic 
tumor tissue samples in which a p-value of 0.00013 was achieved. This is illustrated in Figure 3-
3 where the relative concentration levels of various metabolites are shown for both cohorts 
of mice in this negative control experiment. 
 
Figure 3-2: Ratio of the relative concentrations of various metabolites found in the 
C57BL/6 mice to the relative concentration of various metabolites found in the nude mice 
to for the larger tumor samples 
These control data suggest that the metabolic differences observed are, in fact, immune-
related metabolic properties of pancreatic tumors and not simply genetic differences between the 
breeds of mice. It should also be mentioned that the tumors from both cohorts of mice were more 
metabolically active than the healthy pancreatic tissue, which was to be expected.  
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Figure 3-3: Negative control experimental data that show the relative concentrations of 
various metabolites found in healthy pancreatic tissue 
These data were further validated by performing NMR metabolomics at an earlier stage 
in tumor progression, approximately two weeks after the tumor cells were injected into the flank 
of the mice. The tumors at the time of euthanasia were approximately 1 cm in diameter. 
Spectroscopy was performed for ten mice in total as well, five of which were nude mice and five 
of which were C57BL/6 mice. As in the earlier experiment, the immunocompetent C57BL/6 
mice exhibited significantly higher baseline metabolic activity than the immunocompromised 
nude mice. Specifically, statistically significantly higher relative concentrations were observed in 
the C57BL/6 mice for the following metabolites: lactate (p = 0.0034), alanine (p = 0.00066),  
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Figure 3-4: Relative concentrations of various metabolites found in  
 smaller tumor samples  
total choline (p = 0.00080), valine (p = 0.0035), succinate (p = 0.000024), methionine (p = 
0.0032), glutamate (p = 0.000063), glutathione (p = 0.0000070), oxaloacetate (p = 0.000027), 
glycine (p = 0.0000050), and taurine (p = 0.000095). The relative concentration levels of various 
metabolites are illustrated in Figure 3-4 for both cohorts of mice. Again, the vertical axis depicts 
relative concentration, while the horizontal axis lists some of the common metabolites that were 
found in the spectra.  
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Figure 3-5: Ratio of the relative concentrations of various metabolites found in the 
C57BL/6 mice to the relative concentration of various metabolites found in the nude 
mice for the smaller tumor samples 
The metabolic difference between the immunocompetent mice and the 
immunocompromised mice was even more pronounced at this earlier time point in tumor 
progression, as it was observed that the immunocompetent mice are more metabolically active 
than the immunocompromised mice by an average of 435%. In Figure 3-5, a bar graph is 
depicted that presents the ratio of metabolic concentration for a given metabolite between the 
two cohorts of mice, as in Figure 3-2.  One can see that the immunocompetent mice demonstrate 
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higher baseline metabolic activity than the immunocompromised mice by a factor slightly greater 
than five. 
Because lactate is so important in cancer metabolism, it should be noted that lactate 
concentration is higher by factors of 3.71 and 1.68 in the immunocompetent mice relative to the 
immunocompromised mice at the earlier and later timepoint in tumor progression, respectively.  
 
3.2 Hyperpolarization Data 
 In total, successful hyperpolarization data was acquired for 25 mice, 16 at the earlier time 
point in tumor progression, and 9 at the later time point in tumor progression. The mice imaged 
at the earlier time point came from two separate cohorts, 2 immunocompromised mice and 4 
immunocompetent mice in the first cohort and 5 immunocompromised mice and 5 
immunocompetent mice in the second cohort. Of the mice imaged at the later time point 5 were 
immunocompromised, and 4 were immunocompetent. In addition, an unsuccessful attempt at 
imaging another cohort of mice at the later time point, 3 immunocompromised mice and 3 
immunocompetent mice, was made. The data from this unsuccessful experiment will not be 
presented in this section. However, this experiment will be mentioned further in the discussion 
section. In addition, the reasons why this experiment was a failure and how this failed 
experiment affected the progression of this project will be explored further in that section.  
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Figure 3-6: Glycolytic dependence, smaller tumors 
For both the smaller and larger tumors it was found that the immunocompromised nude 
mice exhibited statistically significantly higher glycolytic dependence than the 
immunocompetent C57BL/6 mice. In particular, p-values of 0.0011 and 0.016 were achieved for 
the earlier and later time points, respectively. Here, glycolytic dependence is quantified via the 
metric nLac, which is defined in Equation 2 found in the introductory hyperpolarization section. 
Figure 3-4 and Figure 3-5 illustrate the nLac differential for the smaller and larger tumors, 
respectively. One should also note that glycolytic dependence increased as tumor size increased 
for both breeds of mice. For the smaller tumors, the hyperpolarization data were acquired using 
two different cohorts, so the result of each is included in the Supplementary Section at the end 
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 Figure 3-7: Glycolytic dependence, larger tumors  
 
Figure 3-8: Dynamic spectroscopy, smaller tumors, cohort 1 
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Figure 3-9: Dynamic spectroscopy, smaller tumors, cohort 2 
of this thesis as Supplementary Figure 1 and Supplementary Figure 2. The dynamic spectra for 
the 25 mice successfully imaged are shown in Figure 3-8, Figure 3-9, and Figure 3-10. In these 
spectra, normalized signal intensity is shown on the vertical axis, and time is shown on the 
horizontal axis. Pyruvate is shown in red, and lactate is shown in blue. The 25 time-integrated 
spectra are shown are shown in Supplementary Figure 3, Supplementary Figure 4, and 
Supplementary Figure 5.  
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Figure 3-10: Dynamic spectroscopy, larger tumors 
 
4. Discussion 
4.1 Histological Staining 
 Following the imaging experiments, the mice were euthanized, and the tumors were 
resected. Some of this tissue was used for NMR spectroscopy, but the rest of it was given to a 
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colleague who subjected it to histological staining. Histology is the study of microscopic 
structures such as cells and tissues [269]. The most widely employed type of histological staining 
experiment is the hematoxylin and eosin (H&E) stain [270]. Hematoxylin is a basic dye that 
stains basophilic structures purplish blue. The cellular nucleus is basophilic and is, thus, stained 
with hematoxylin. Eoisin is an acidic dye that stains acidophilic structures red or pink. The 
cytoplasm and most connective tissue fibers are acidophilic and are stained with eoisin.  
 
Figure 4-1: H&E staining of tumors at the earlier time point in tumor progression 
 
 H&E staining was performed on five tumor samples from immunocompetent mice at the 
earlier time point in tumor progression, five tumor samples from immunocompromised mice at 
the earlier time point in tumor progression, five tumor samples from immunocompetent mice at 
the later time point in tumor progression, and five tumor samples from immunocompromised 
mice at the later time point in tumor progression. Representative H&E stains from tumor samples 
taken at the earlier time point in tumor progression and the later time point in tumor progression 
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are shown in Figure 4-1 and Figure 4-2, respectively. In both of these figures, the tumors taken 
from the immunocompetent mice are shown on the left, and the tumors taken from the 
immunocompromised mice are shown on the right.  
 
Figure 4-2: H&E staining of tumors at the later time point in tumor progression 
 
One can distinguish between immune cells and cancer cells in these H&E stains by 
looking at their morphological features. In particular, immune cells are small and dense, while 
cancer cells have a large nucleus and an irregular size and shape. In the tumors taken from the 
C57BL/6 mice, as one would expect, we see that the immune components are very successful at 
infiltrating all areas of the tumor. This infiltration becomes more pronounced as the tumor 
becomes larger. Conversely, in the tumors taken from the nude mice, which lack the ability to 
produce many viable T cells, there is much less immune infiltration. This can be seen even more 
clearly in the color-coded H&E stains shown in Figure 4-3 and Figure 4-4. Figure 4-3 shows a 
stain of a tumor taken from an immunocompetent mouse at the later time point in tumor 
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progression, while Figure 4-4 shows a stain of a tumor taken from an immunocompromised 
mouse at the later time point in tumor progression. Here, immune components are shown in 
green, cancer cells are shown in red, and elongated stromal cells are shown in blue. In the tumor 
 
Figure 4-3: Color coded H&E stain of a tumor taken from the immunocompetent mice 
 
taken from the immunocompetent mouse, the immune components clearly infiltrate all areas of 
the tumor, while in the tumor taken from the immunocompromised mouse, the immune  
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 Figure 4-4: Color coded H&E stain of a tumor taken from the immunocompromised mice 
 
components, which are presumably B cells, are restricted to the periphery. These observed 
differences in the level of immune infiltration have tremendous consequences, and these effects 
will be the topic of discussion in the following section.  
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4.2 The Effects of Immune Infiltration 
The finding that the tumors cultivated in an immunocompetent environment exhibit 
higher baseline metabolic activity than in the nude mice can be explained in reference to the 
histological stains presented in the previous section. Tumors are typically strongly infiltrated 
with immune cells, and this infiltration mimics the inflammatory conditions that are seen in 
noncancerous tissue [271]. Thus, tumors can be thought of as wounds that never heal [272].  It is 
well known and, in fact, is now considered one of the hallmarks of cancer [124], that tumor cells 
have built-in machinery that allow them to evade this immune response. However, the problem 
runs deeper than this; paradoxically, the aforementioned inflammatory response induced by the 
immune cells actually promotes tumorigenesis and progression [273-276].  In particular, the 
inflammatory response adds bioactive materials to the tumor microenvironment, such as growth 
factors, survival factors, proangiogenic factors, and extracellular matrix modifying enzymes that 
promote invasion and metastasis [124,277]. In addition, inflammatory cells release mutagenic 
reactive oxygen species, which facilitate the tumor’s genetic progression towards a greater state 
of malignancy [124,276].  
As shown in Figure 4-1, Figure 4-2, and Figure 4-3, immune cells are successful at 
infiltrating the tumors cultivated in the immunocompetent mice, thus mimicking inflammatory 
conditions. Therefore, the tumors cultivated in the immunocompetent environment benefit from 
the tumorigenic properties discussed in the above paragraph. With the upregulation of growth 
factors, survival factors, proangiogenic factors, and mutagenic factors, it should come as no 
surprise that this reflected downstream as an upregulation of metabolic activity. The NMR 
spectroscopic data seem to suggest that the tumors cultivated in the immunocompetent 
background start out with a greater amount of glucose than the tumors cultivated in the 
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immunocompromised background since one observes an upregulation of metabolism across the 
board. This may be accomplished via an upregulation of glucose transporter proteins such as 
GLUT1, as to provide the necessary fuel required for the enhanced tumor progression induced by 
the inflammatory conditions. This greater initial amount of glucose present in the tumors 
cultivated in the immunocompetent mice would also explain why the tumors cultivated in the 
immunocompromised mice demonstrate a higher propensity for utilizing lactate as a glucose 
alternative, which is discussed in greater detail in the next section.  
 
4.3 Lactate Metabolism 
There were two major findings in this project. The first is that the tumors cultivated in the 
immunocompetent mice exhibit significantly higher baseline metabolic activity than the tumors 
cultivated in the immunocompromised mice. This was initially counterintuitive to me since I 
assumed that one would expect higher metabolic activity in the nude mice since tumor cells 
would be more successful at proliferating given that they lack an immune system. However, as 
discussed above, the immune components located in the tumor microenvironment, which are 
present in the C57BL/6 mice but missing in the nude mice, allow the tumor to mimic an inflamed 
state. This inflammation promotes tumorigenesis by supplying growth factors, survival factors, 
and proangiogenic factors to the tumor microenvironment, which is reflected downstream as 
upregulated metabolic activity relative to a system in which these immune components are 
missing. 
The second major finding of this project is that the tumors cultivated in the 
immunocompromised mice displayed a greater level of glycolytic dependence than the tumors 
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cultivated in the immunocompetent mice. At first glance these two findings seem to clash with 
one another. How is it possible that one observes significantly higher pyruvate-to-lactate 
conversion in one group but a significantly higher lactate pool size in the other? This is 
extremely exciting, however, as it proves that additional information can be garnered via the 
implementation of real-time dynamic spectroscopic imaging with hyperpolarized pyruvate.  
Here, it can clearly be seen that the dynamic spectroscopic data are not simply redundantly 
corroborating the ex vivo data acquired using more conventional static spectroscopic techniques. 
Thus, the implementation of dynamic spectroscopic imaging with hyperpolarized pyruvate in 
patients will add undeniable value to the clinic, augmenting the radiologist’s ability to study 
metabolic dysregulation in tumors. Whether this augmentation justifies the cost of DNP systems 
and outweighs the additional challenges introduced remains to be seen. It should also be clearly 
noted that hyperpolarization and NMR spectroscopy are measuring different things. Namely, 
hyperpolarization is measuring a dynamic metabolic flux in real-time, while NMR spectroscopy 
is simply looking at a static snapshot of tumor metabolism. Information about where a given 
metabolite came from cannot be discerned from NMR spectroscopy; one measures only a static 
pool size. 
The lack of correlation between the in vivo data and the ex vivo data certainly came as a 
surprise. Firstly, this is due to the unpublished data acquired in our laboratory studying a 
different cancer system that showed a direct correlation between nLac and lactate pool size in 
pancreatic tumors of varying aggressiveness. Also, historically, lactate is often viewed as a dead-
end waste product of glycolytic metabolism [278]. This is not the case, however, as lactate can 
serve as an alternative to glucose as a carbohydrate fuel source in both cancerous cells [279-281] 
and noncancerous cells [282] alike. It has been shown that the tumors in the 
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immunocompromised mice exhibit significantly lower baseline metabolic activity than the 
tumors in the immunocompetent mice. Thus, it is probable that the tumors in the 
immunocompromised mice take up less glucose than their immunocompetent counterparts, given 
that one observes smaller pool sizes of glucose’s byproducts in the tumors in the 
immunocompromised mice. Having less glucose available from the beginning, it would make 
sense that the tumors in the immunocompromised mice would have a higher propensity for 
utilizing the available lactate. In 1985, Brooks introduced the lactate shuttle hypothesis, in which 
he contended that lactate metabolism is a critically important component in the integration and 
regulation of intermediary metabolism [283]. Further research has elucidated two distinct 
mechanisms [284] through which lactate can be metabolized: the cell-cell lactate shuttle 
[285,286] and the intracellular lactate shuttle [287,288].  
The cell-cell lactate shuttle is a mechanism through which lactate leaves a glycolytic cell 
and is shuttled into another. It has long been understood in the context of exercise [289,290]. 
Because of its large mass and its high metabolic activity, skeletal muscle is the major utilizer of 
the cell-cell lactate shuttle [291]. Namely, white muscle fibers produce lactate and transport it 
into the blood [292]. The monocarboxylate transporters (MCTs) constitute a family of membrane 
transport proteins that shuttle monocarboxylates, such as pyruvate and lactate, across biological 
membranes [293,294]. Lactate is shuttled out of the glycolytic muscle cells via the transporter 
MCT4 and shuttled into erythrocytes via the transporter MCT1 [295]. In addition to the red 
blood cells, the heart and the brain have also been shown to consume lactate [296-298]. More 
recently, it has been demonstrated that this mechanism is exploited in cancer in which glycolytic 
tumor cells transport lactate to either oxidative tumor cells or endothelial cells lining tumor blood 
vessels [299]. Analogously to the mechanism described above, MCT4 mediates the movement of 
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lactate out of the glycolytic tumor cells, and MCT4 mediates the deposition of lactate into the 
oxidative tumor cells [279]. Here, the oxidative tumor cells have been shown to utilize the lactate 
as their main source of metabolic fuel [300].  
 The intracellular lactate shuttle describes the process through which lactate is back 
converted into pyruvate [301]. Enzyme-mediated kinetics exhibit a strong concentration 
dependence, and the pyruvate-to-lactate forward conversion is typically more favorable than the 
lactate-to-pyruvate back conversion [302]. However, pyruvate is taken up by the mitochondria to 
be further metabolized via the tricarboxylic acid (TCA) cycle [303], while lactate is not. Thus, if 
one looks at the mitochondria as a pyruvate sink, then at the interface of the cytosol and the 
plasma membrane of the mitochondria the ratio of the concentration of lactate to the 
concentration of pyruvate is unusually high. Thus, the lactate-to-pyruvate back conversion, 
which is mediated by the enzyme lactate dehydrogenase B [304] (LDHB), becomes more 
kinetically favorable in this subcellular region
300
. Being in its immediate vicinity, this newly 
created pyruvate can then be taken up by the mitochondria and driven through the TCA cycle 
[305]. Thus, through both the cell-cell lactate shuttle and the intracellular lactate shuttle, one sees 
that lactate cannot be thought of as simply a dead end waste product of glycolytic metabolism 
and can, instead, be utilized as an alternative to glucose to fuel further downstream metabolism. 
Whether or not this is what is happening in these tumors will need to be verified in future 
studies.  
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4.4 Problems and Pitfalls 
Science often progresses along a circuitous path, and this project was certainly no 
exception. As was mentioned previously, the biggest drawback of dynamic spectroscopic 
imaging with hyperpolarized pyruvate is that the hyperpolarized signal decays rapidly. Namely, 
the characteristic T1 decay of the hyperpolarized pyruvate is typically on the order of tens of 
seconds to minutes. Thus, the successful implementation of this technique relies on the 
assumption that the pyruvate can be delivered to the tumor in a time that is short relative to the 
T1 of the hyperpolarized pyruvate. This assumption can be violated when the tumor is poorly 
vascularized.  
 
Figure 4-5: Dynamic spectroscopy, failed experiment due to low SNR 
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Poor vascularization hampered many of the experiments from this project, since some of 
the tumors were extremely necrotic at later stages of tumor progression. When this happens, no 
spectroscopic signal is observed after the injection of pyruvate. Luckily, these experiments were 
performed on animal subjects, so in the event of a failed injection, we were able to simply keep 
the mouse anesthetized and on the scanner for a repeat experiment. However, as this technology 
is implemented into the clinic, a more effective method to deliver the pyruvate to poorly 
vascularized tumors may need to be developed.  
 
Figure 4-6: Glycolytic dependence, failed experiment due to low SNR 
This issue not only was a nuisance; it shaped the entire course of this project. The first 
hyperpolarization experiment that was performed has not been shown above, since the data are 
not reliable. Because the large tumors were extremely necrotic, the pyruvate had difficulty 
perfusing to the tumor, and the signal-to-noise (SNR) ratio of the experiments was unacceptably 
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low. The acquired dynamic spectra are shown in Figure 4-5, where one can see extraordinarily 
low SNR in the third nude mouse and the first C57BL/6 mouse. As can be seen in Figure 4-6, 
these data suggest that the immunocompetent mice exhibit higher glycolytic dependence than the 
nude mice. To counteract these SNR issues, the next set of hyperpolarized experiments were 
performed at an earlier time point in tumor progression. At this time point, the tumors were 
small, and necrosis was not as much of an issue. Here, the SNR issues were circumvented, but a 
reversal of the previous result was observed, as the nude mice exhibited higher glycolytic 
dependence than the immunocompetent mice. These seemingly contradictory results led to the 
hypothesis that the immune-related metabolic properties of pancreatic tumors displayed temporal 
dependence with respect to tumor development. Later, more rigorous experiments disproved this 
hypothesis and showed that both NMR metabolomics experiments and hyperpolarization 
experiments largely did not depend on time with respect to tumor development.  However, this 
line of reasoning explains why each experiment done in this project was repeated both at an 
earlier time point and a later time point in tumor development. 
 
4.5 Future Direction 
 As discussed previously, the main finding of this project was that the pancreatic tumors 
cultivated in the immunocompetent setting exhibited significantly higher baseline ex vivo 
metabolic activity than the pancreatic tumors cultivated in the immunocompromised setting, 
while the pancreatic tumors cultivated in the immunocompromised setting demonstrated a 
significantly higher glycolytic conversion flux in vivo than the pancreatic tumors cultivated in 
the immunocompetent setting. Because this result was completely unexpected, it generated many 
new questions to ask and avenues to explore in order to further elucidate how the immune 
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environment affects pancreatic tumor metabolism. In Section 4.3, the two major mechanisms 
through which lactate is metabolized were discussed. To interrogate the relative importance of 
the cell-cell lactate shuttle, we will use antibodies to stain for both MCT4 and MCT1. Similarly, 
to interrogate the relative importance of the intracellular lactate shuttle, we will use an antibody 
to stain for LDHB. Also, the NMR metabolomics data suggests that the tumors cultivated in the 
immunocompetent environment may take up more glucose than the tumors cultivated in the 
immunocompromised environment. To test this possibility, we will also stain the tumors for 
glucose trasporter 1 (GLUT1), a proteins that mediates the uptake of glucose into cells [306].  
 As shown in Section 4.1, the tumors cultivated in the immunocompetent environment are 
heavily infiltrated by immune cells. On one hand, as has been discussed, the heavy infiltration of 
immune cells seen in the immunocompetent mice initiates tumor-promoting inflammatory 
conditions. On the other hand, T cell activation has its own metabolic demands, as it has been 
shown that mitogenic-stimulated T cell activation is accompanied by an increase in glucose 
utilization [307-311]. Thus, when performing NMR spectroscopy on these samples, one cannot 
determine the relative contributions to the metabolic profile by the immune cells and the cancer 
cells. Thus, to determine the metabolic signature of each cell type, we will employ flow 
cytometry to separate the two cell types and will perform NMR spectroscopy on each.  
 There are multiple types of T lymphocytes located in the tumor microenvironment of the 
pancreatic tumors cultivated in the C57BL/6 mice. As described in Section 1.2, CD4+ T cells, 
also known as helper T cells, aid in the activation of B and T lymphocytes and induce B and T 
cell proliferation [97].  CD8+ T cells, also known as cytotoxic T cells [312], directly attack and 
kill antigens [98].  It would be advantageous to determine how each type of T cell contributes to 
the metabolic function of the tumor. This can be accomplished by inactivating a given type of T 
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lymphocyte while keeping other types active. Inactivation of specific T cell types can be 
accomplished in one of two ways. In vivo T cell depletion can be accomplished via an 
intraperitoneal administration of monoclonal antibodies [313]. Alternatively, one can use CD4 or 
CD8 knockout mice [314], in which the mouse’s genome has been altered to suppress the 
expression of the genes that encode for the proteins utilized by helper T cells or cytotoxic T cells, 
respectively. Thus, the CD4 knockout blocks helper T cell development, and the CD8 knockout 
blocks cytotoxic T cell development. The contribution to the metabolic function of a tumor by a 
given T cell type will be ascertained by inactivating that specific T cell type and performing in 
vivo hyperpolarization experiments and ex vivo NMR spectroscopic experiments.  
 Lastly, we will continue to work on a project studying how the microbiome influences 
the efficacy of immunotherapy in pancreatic cancer. Shortly after one’s birth the human 
intestinal tract is colonized by nearly 100 trillion commensal microorganisms [315-325]. 
Astonishingly, the number of bacteria living in one’s gut is greater than the number of eukaryotic 
cells in the body [326,327].   This microbiome is known to affect the host immune system since 
these microbial communities in one’s gut co-evolve with the immune system [328]. Specifically, 
it has been shown that the composition of the intestinal microbiota alters the balance between 
interleukin-17-producing effector T helper cells and Foxp3
+
 regulatory T cells [329,330]. In our 
experiments, the microbiome is modulated by isolating the mice in a gnotobiotic facility, which 
implies that they are kept in a germfree environment [331].  These mice are then treated with 
immunotherapeutic agents, and the tumors are resected following euthanasia. These samples are 
then subjected to NMR spectroscopy for metabolic analysis in order to assess the efficacy of the 
immunotherapy.  
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5. Conclusion 
 Pancreatic cancer has an extremely high associated morbidity, due in part to the fact that 
it is resistant to both radiotherapy and many of the chemotherapeutic agents that are available in 
the clinic. Immunotherapy, on the other hand, has exhibited tremendous success in treating 
melanoma and various other forms of cancer, so it had been hoped that immunotherapy would be 
equally successfully implemented into pancreatic cancer. Unfortunately, this has not been the 
case. There is an initiative that aims to try to understand from a more mechanistic perspective 
why immunotherapy is not effective in treating pancreatic cancer. This, however, is an extremely 
complex problem that must be attacked from a variety of angles. Because metabolic 
dysregulation is a hallmark of malignant cells and because metabolomics is downstream from 
genomics and proteomics, it is advantageous to better understand how the immune system alters 
the metabolic function of a pancreatic tumor.  
 We have shown that the immune environment in which a pancreatic tumor is harvested 
strongly affects its metabolic expression. In particular, we have shown that pancreatic tumors 
cultivated in mice with a functioning immune system exhibit significantly higher baseline 
metabolic activity than pancreatic tumors cultivated in nude mice that lack the ability to produce 
viable T cells. The histological stains of these tumors indicate a high level of immune infiltration 
in the samples taken from the immunocompetent mice and much lower levels of immune 
involvement in the samples taken from the immunocompromised mice. The higher levels of 
immune infiltration seen in the tumors taken from the immunocompetent mice mimic the 
inflammatory conditions observed in wound healing. Inflammation is known to supply bioactive 
molecules to the tumor microenvironment. This phenomenon is reflected downstream as an 
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upregulation of metabolic activity, as observed here as larger static metabolite pool sizes in the 
NMR spectroscopic analysis of the tumor tissue samples. 
 In addition, we have shown that the tumors cultivated in the immunocompromised setting 
demonstrate a significantly higher pyruvate-to-lactate conversion flux than the tumors cultivated 
in the immunocompetent setting. This measurement combined with the fact that the static lactate 
pool size is significantly smaller in the tumors cultivated in the immunocompromised mice 
relative to the tumors cultivated in the immunocompetent mice implies that the 
immunocompromised mice must further metabolize lactate somehow. Future histological stains 
will elucidate the relative importance of the cell-cell lactate shuttle and the intracellular lactate 
shuttle in pancreatic tumor metabolism.  
 Ultimately, this project has illustrated the delicate interplay between immunology and 
pancreatic cancer metabolic expression. In particular, the immune environment in which a 
pancreatic tumor is harvested strongly affects its metabolic signature, as this study has identified 
clear biomarkers that can facilitate the assessment of metabolic changes between 
immunocompromised and immunocompetent pancreatic tumors. Because cancer cells exhibit a 
significant increase in metabolic activity relative to normal tissue, an understanding of the 
metabolic function of tumors in systems with different levels of immunocompetence serves as a 
critical first step to develop an understanding of the immune-related metabolic properties of the 
tumor, which have potential application in assessing a tumor’s response to immunotherapy. 
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6. Supplementary Section 
 
 
 Supplementary Figure 1: Glycolytic dependence, small tumors, cohort 1  
 
Supplementary Figure 2: Glycolytic dependence, small tumors, cohort 2 
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 Supplementary Figure 3: Time-integrated spectra, small tumors, cohort 1 
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Supplementary Figure 4: Time-integrated spectra, small tumors, cohort 2 
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Supplementary Figure 5: Time-integrated spectra, large tumors 
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